Abstract
This study investigated the application of crude methanol extract (CME) of Zapoteca portoricensis root and its methanol (MF) and ethyl acetate (EAF) fractions in managing benign prostatic hyperplasia (BPH). Forty-five albino rats (180-200 g) were divided into nine groups of five rats each: Group 1 served as normal control. BPH was induced in groups 2–9 using dihydrotestosterone and estradiol. Group 2 served as BPH-control and group 3 was dutasteride-treated. Groups 4 and 5, 6 and 7, and 8 and 9 were respectively treated with 200 and 400 mg/kg/d b.w. of CME, 200 and 400 mg/kg/d b.w. of MF, and 200 and 400 mg/kg/d b.w. of EAF, respectively for 14 days orally. The effects of the extracts on the hematological and biochemical indices of the rats were assessed. At 400 mg/kg/d b.w, p.o. using a gavage, CME, MF and EAF decreased prostatic specific antigen by 55.91%, 57.54% and 56.75%, respectively comparable to 58.80% by dutasteride (an indication of improved prostate status). The extracts also restored BPH-modified hematological and biochemical status of BPH-induced-extracts-treated rats compared to BPH-control. These findings suggest that Z. portoricensis root extracts normalize aberrations associated with BPH and may justify the plant’s folkloric use in the management of BPH.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call